目的 探討他克莫司滴眼液聯(lián)合鹽酸奧洛他定滴眼液治療過(guò)敏性結(jié)膜炎的臨床療效。方法 選取2015年1月-2016年12月四川大學(xué)華西醫(yī)院眼科收治的過(guò)敏性結(jié)膜炎患者120例為研究對(duì)象，按隨機(jī)數(shù)字法將所有患者分為對(duì)照組和治療組，每組各60例。對(duì)照組給予鹽酸奧洛他定滴眼液，1~2滴/次，3次/d。治療組在對(duì)照組基礎(chǔ)上給予他克莫司滴眼液，1滴/次，2次/d。兩組患者均連續(xù)治療1周。觀察兩組的臨床療效，比較兩組的Schirmer試驗(yàn)、淚膜破裂時(shí)間（BUT）、角膜熒光素染色評(píng)分和癥狀體征改善時(shí)間。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.67%、96.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組Schirmer試驗(yàn)、BUT明顯升高，角膜熒光素染色評(píng)分、癥狀評(píng)分明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組結(jié)膜充血、眼癢、流淚改善時(shí)間均明顯短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 他克莫司滴眼液聯(lián)合鹽酸奧洛他定滴眼液治療過(guò)敏性結(jié)膜炎具有較好的臨床療效，可改善臨床癥狀，縮短癥狀體征改善時(shí)間，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Tacrolimus Eye Drops combined with Olopatadine Hydrochloride Eye Drops in treatment of allergic conjunctivitis. Methods Patients (120 cases) with allergic conjunctivitis in Department of Ophthalmology of West China Hospital of Sichuan University from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given Olopatadine Hydrochloride Eye Drops, 1-2 drops/time, three times daily. Patients in the treatment group were given Tacrolimus Eye Drops on the basis of the control group, 1 drop/time, twice daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacies were evaluated, and Schirmer test, BUT, corneal fluorescein staining score, and symptom improvement time in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 96.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, Schirmer test and BUT in two groups were significantly increased, but symptom score and corneal fluorescein staining score in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the symptom improvement time of conjunctiva hyperemia, ophthalmic itching, and tears in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Tacrolimus Eye Drops combined with Olopatadine Hydrochloride Eye Drops has clinical curative effect in treatment of allergic conjunctivitis, can improve clinical symptoms, and shorten symptom improvement time, which has a certain clinical application value.